1A9-OxR cells were also cross-resistant to both cisplatin and carboplatin (Fig. S4C), and this corresponded with decreased uptake of cisplatin and carboplatin (Fig. S4D), further demonstrating that the role of LAT3 in the divergent modes of action for oxaliplatin may be cancer-type specific. This evidence concerns the gene SLC43A1 and cancer.